Doranidazole
Doranidazole (PR 350) is a radiosensitizer. Doranidazole increases the radiosensitivity of hypoxic SCCVII cells. Doranidazole significantly enhances radiation-induced growth delay in SCCVII tumors when administered intravenously before tumor irradiation. Doranidazole radiosensitizes tumors to an extent that depends on the tumor's oxygenation status. Doranidazole can be used for the study of lymphoma and hypoxic pancreatic tumors[1][2][3].
Product Specifications
CAS Number
149838-23-3
Product Name Alternative
PR 350; RP 343
UNSPSC
12352005
Target
Biochemical Assay Reagents
Related Pathways
Others
Field of Research
Cancer
Smiles
OC[C@H](O)[C@@H](CO)OCN1C([N+]([O-])=O)=NC=C1
Molecular Formula
C8H13N3O6
Molecular Weight
247.21
References & Citations
[1]Yahiro T, et al. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo. J Radiat Res. 2005 Sep;46 (3) :363-72.|[2]Mizuho Aoki, et al. Effect of a Hypoxic Cell Sensitizer Doranidazole on the Radiation-induced Apoptosis of Mouse L5178Y Lymphoma Cells, Journal of Radiation Research, Volume 43, Issue 2, June 2002, Pages 161–166.|[3]Shibamoto Y, et al. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol. 2000 Aug;56 (2) :265-70.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
